Are we optimizing the wrong molecules? Re-thinking lead selection for next-generation therapeutics
02 Sept 2026
Lead Identification & Optimization
- Why many “best-in-class” binders still fail clinically
- The industry shift from affinity optimization toward systems-level biology and tissue selectivity
- Whether potency obsession has created blind spots in immunotherapy and solid tumors
- How teams decide when a target is biologically compelling but clinically too risky
- Emerging strategies to engineer where and when activity occurs, not just how strongly
Industry Expert
